AlphAIAlphAI — Financial news for AI agents
investing.comOCT 271 min read$IQV

IQVIA Holdings earnings beat by $0.09, revenue topped estimates

IQVIA Holdings (NYSE: IQV) reported Q3 EPS of $3.34, beating estimates by $0.09, with revenue at $4.43B, exceeding expectations. The company provided FY 2026 guidance, with EPS and revenue estimates slightly below consensus. The stock is up 15.06% over the last 3 months and 25.43% over the last 12 months, with a 'good performance' financial health score according to InvestingPro.

Original reporting
investing.com
Published Oct 27, 2026, 11:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 11:16 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$IQV
Bullish
high confidence
Mentioned
$IQV
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$IQVBullishHigh
01

Why it matters

The earnings beat reinforces the company's growth narrative and may attract momentum traders.

02

Market read

Strong earnings could drive short‑term buying interest in IQV.

03

What to watch

Potential headwinds from payer reimbursement pressures could limit upside.

Relevance 8/10Novelty 8/10Timing: post-market reaction

Background

IQVIA is a leading provider of health‑care data and analytics services.

Company-level read

Ticker impact

$IQVBullishHigh confidence
Context

IQVIA reported Q3 EPS of $3.34 beating estimates by $0.09 and revenue of $4.43B above consensus.

Expected impact

likely upward move as market prices in the beat

Evidence & confidence

Both EPS and revenue exceeded expectations, and guidance is in line with consensus, supporting a bullish reaction.

Market effects

Sector

Positive for health‑care services and data analytics sector.

Regional

U.S. market may see modest lift in health‑care indices.

Global

Limited to investors tracking U.S. health‑care data firms.

Counterpoint

What could challenge this read

If guidance falls short of growth expectations, the beat may be priced out quickly.

Key entities

  • Company
    IQVIA Holdings

    Health‑care data and analytics firm.

Read at source← All news

StoryIQVIA reports Q3 2026 beat and lifts full‑year revenue and EPS outlook

Also covered by

5 outlets

Related articles

OCT 28
$IQVMedAI 8/10

IQVIA Holdings Inc (IQV) (Q3 2026) Earnings Call Highlights: Record Bookings, Raised

IQVIA Holdings Inc. reported Q3 2026 earnings with record bookings and raised guidance. Revenue was $4.428B, up 8% YoY, and adjusted EBITDA rose 8.7%. Challenges include FX headwinds and R&D backlog adjustments. Management highlighted AI adoption and strong biotech demand. Full-year 2026 guidance was increased, with revenue expected between $17.35B-$17.5B. No 2027 guidance was provided.

finance.yahoo.com2 min
OCT 27
$IQVHighAI 8/10

What IQVIA (IQV) Said on Its Q3 Earnings Call

IQVIA reported Q3 revenue growth of 6.9% to $1.79B, with organic growth at 4%. AI adoption contributed to commercial and clinical momentum, with 415 AI agents deployed. The company raised its 2026 outlook, expecting revenue of $17.35B-$17.50B and adjusted EPS of $12.90-$13.00. Cash flow from operations was $825M, with free cash flow at $667M.

finance.yahoo.com2 min
OCT 27
$IQVHighAI 9/10

IQVIA (IQV) Q3 2026 Earnings Call Transcript

IQVIA reported Q3 2026 revenue of $4.43B, up 8%, with organic growth at 6%. Adjusted EBITDA grew 8.7% to $1.03B, and adjusted EPS rose 11.3% to $3.34. R&D solutions revenue increased 8.7%, and commercial solutions revenue grew 6.9%. The company raised full-year revenue guidance to $17.35B-$17.5B. AI deployments and emerging biopharma funding growth were highlighted.

fool.com2 min
OCT 27
$IQVHighAI 8/10

IQVIA Holdings Inc. Q3 2026 Earnings Call Summary

IQVIA Holdings Inc. reported Q3 2026 organic revenue growth of 6%, driven by clinical segment momentum and AI integration. The Emerging Biopharma segment saw record demand with $90B funding YTD. Full-year guidance was raised, with AI expected to support future margin expansion. Management highlighted competitive advantages through AI and strategic partnerships. Q4 interest expense is projected at $210M. A $2.1B backlog scrub was conducted to improve visibility.

finance.yahoo.com3 min